China SFDA Mulls Preferential Treatment For Makers Of Pediatric Drugs
This article was originally published in PharmAsia News
China's State FDA is considering providing easier market access to makers of drugs aimed at children as one way to promote a type of drug mostly non-existent in the country.
You may also be interested in...
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.
The German biotech has developed its COVID-19 vaccine in record-breaking time, but artificial intelligence could help accelerate drug discovery over the longer term.
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.